Objective and quantitative evaluation of motor function in a monkey model of Parkinson's disease

Journal of Neuroscience Methods

Volumn 190, Issue 2, 2010, Pages 198-204

  Saiki, Hidemoto ^a,b,c   Hayashi, Takuya ^d   Takahashi, Ryosuke ^b   Takahashi, Jun ^c  

^a Kitano Hospital   (Japan)

^b KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c KYOTO UNIVERSITY   (Japan)

^d RIKEN   (Japan)

Author keywords

Dopamine transporter; MPTP; Parkinson's disease; Primate model; Video based analysis

Indexed keywords

1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; DOPAMINE TRANSPORTER; (1R-(EXO,EXO))-3-(4-FLUOROPHENYL)-8-METHYL-8- AZABICYCLO(3.2.1)OCTANE-2-CARBOXYLIC ACID, METHYL ESTER; CARBON; COCAINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; CORRELATION ANALYSIS; MESENCEPHALON; MONKEY; MOTOR PERFORMANCE; NONHUMAN; PARKINSON DISEASE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PUTAMEN; QUANTITATIVE ANALYSIS; RATING SCALE; VIDEORECORDING; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; BRAIN MAPPING; CHEMICALLY INDUCED; DISEASE MODEL; DYSKINESIA, DRUG-INDUCED; MACACA FASCICULARIS; METABOLISM; PARKINSONIAN DISORDERS; PATHOPHYSIOLOGY; SCINTISCANNING; SEVERITY OF ILLNESS INDEX;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; BRAIN MAPPING; CARBON RADIOISOTOPES; COCAINE; DISEASE MODELS, ANIMAL; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DYSKINESIA, DRUG-INDUCED; MACACA FASCICULARIS; PARKINSONIAN DISORDERS; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; VIDEO RECORDING;

EID: 77954217803     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.05.009     Document Type: Article

References (35)

1. Andersson D.R., Nissbrandt H., Bergquist F. Partial depletion of dopamine in substantia nigra impairs motor performance without altering striatal dopamine neurotransmission. Eur J Neurosci 2006, 24:617-624.
2. Brownell A.L., Canales K., Chen Y.I., Jenkins B.G., Owen C., Livni E., et al. Mapping of brain function after MPTP-induced neurotoxicity in a primate Parkinson's disease model. Neuroimage 2003, 20:1064-1075.
3. 18F]fluoro-l-dopa uptake in early Parkinson's disease shows nonlinear progression in the putamen. Mov Disord 2009, 24:1009-1015.
4. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proc Natl Acad Sci USA 1983, 80:4546-4550.
5. Chassain C., Eschalier A., Durif F. Assessment of motor behavior using a video system and a clinical rating scale in parkinsonian monkeys lesioned by MPTP. J Neurosci Methods 2001, 111:9-16.
6. Cheramy A., Leviel V., Glowinski J. Dendritic release of dopamine in the substantia nigra. Nature 1981, 289:537-542.
7. Chiueh C.C., Burns R.S., Markey S.P., Jacobowitz D.M., Kopin I.J. Primate model of parkinsonism: selective lesion of nigrostriatal neurons by 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine produces an extrapyramidal syndrome in rhesus monkeys. Life Sci 1985, 36:213-218.
8. Cobb W.S., Abercrombie E.D. Distinct roles for nigral GABA and glutamate receptors in the regulation of dendritic dopamine release under normal conditions and in response to systemic haloperidol. J Neurosci 2002, 22:1407-1413.
9. DeLong M.R. Primate models of movement disorders of basal ganglia origin. Trends Neurosci 1990, 13:281-285.
10. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: a multi-tracer PET study. Neuroimage 2006, 30:26-35.
11. Elsworth J.D., Taylor J.R., Sladek J.R., Collier T.J., Redmond D.E., Roth R.H. Striatal dopaminergic correlates of stable parkinsonism and degree of recovery in old-world primates one year after MPTP treatment. Neuroscience 2000, 95:399-408.
12. 18F]CFT reflect nigral neuronal loss in a rat model of Parkinson's disease. Synapse 2004, 51:119-127.
13. Gunn R.N., Lammertsma A.A., Hume S.P., Cunningham V.J. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. Neuroimage 1997, 6:279-287.
14. Hayashi T., Ohnishi T., Okabe S., Teramoto N., Nonaka Y., Watabe H., et al. Long-term effect of motor cortical repetitive transcranial magnetic stimulation [correction]. Ann Neurol 2004, 56:77-85.
15. Imbert C., Bezard E., Guitraud S., Boraud T., Gross C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. J Neurosci Methods 2000, 96:71-76.
16. Jankovic J., Kapadia A.S. Functional decline in Parkinson disease. Arch Neurol 2001, 58:1611-1615.
17. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism Relat Disord 2003, 9:131-137.
18. Kang G.A., Bronstein J.M., Masterman D.L., Redelings M., Crum J.A., Ritz B. Clinical characteristics in early Parkinson's disease in a central California population-based study. Mov Disord 2005, 20:1133-1142.
19. Kuhar M.J., Sanchez-Roa P.M., Wong D.F., Dannals R.F., Grigoriadis D.E., Lew R., et al. Dopamine transporter: biochemistry, pharmacology and imaging. Eur Neurol 1990, 30(Suppl. 1):15-20.
20. Liu N., Yue F., Tang W.P., Chan P. An objective measurement of locomotion behavior for hemiparkinsonian cynomolgus monkeys. J Neurosci Methods 2009, 183:188-194.
21. 123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001, 57:2089-2094.
22. 18F]CFT PET. Synapse 2003, 48:109-115.
23. Oiwa Y., Eberling J.L., Nagy D., Pivirotto P., Emborg M.E., Bankiewicz K.S. Overlesioned hemiparkinsonian non human primate model: correlation between clinical, neurochemical and histochemical changes. Front Biosci 2003, 8:a155-a166.
24. Prensa L., Parent A. The nigrostriatal pathway in the rat: a single-axon study of the relationship between dorsal and ventral tier nigral neurons and the striosome/matrix striatal compartments. J Neurosci 2001, 21:7247-7260.
25. 18F]CFT are both sensitive PET markers to detect presynaptic dopaminergic hypofunction in early Parkinson's disease. Synapse 2001, 40:193-200.
26. Robertson H.A. Dopamine receptor interactions: some implications for the treatment of Parkinson's disease. Trends Neurosci 1992, 15:201-206.
27. 123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995, 38:589-598.
28. Smith S.M. Fast robust automated brain extraction. Hum Brain Mapp 2002, 17:143-155.
29. Takagi Y., Takahashi J., Saiki H., Morizane A., Hayashi T., Kishi Y., et al. Dopaminergic neurons generated from monkey embryonic stem cells function in a Parkinson primate model. J Clin Invest 2005, 115:102-109.
30. Timmerman W., Abercrombie E.D. Amphetamine-induced release of dendritic dopamine in substantia nigra pars reticulata: D1-mediated behavioral and electrophysiological effects. Synapse 1996, 23:280-291.
31. Togasaki D.M., Hsu A., Samant M., Farzan B., DeLanney L.E., Langston J.W., et al. The Webcam system: a simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. J Neurosci Methods 2005, 145:159-166.
32. van Rooden S.M., Visser M., Verbaan D., Marinus J., van Hilten J.J. Motor patterns in Parkinson's disease: a data-driven approach. Mov Disord 2009, 24:1042-1047.
33. Vandecasteele M., Glowinski J., Deniau J.M., Venance L. Chemical transmission between dopaminergic neuron pairs. Proc Natl Acad Sci USA 2008, 105:4904-4909.
34. Worsley K.J. Statistical analysis of activation images. Functional MRI: an introduction to methods 2001, Oxford University Press, Oxford, (Chapter 14). P. Jezzard, P.M. Matthews, S.M. Smith (Eds.).
35. 11C-CFT. Exp Neurol 1994, 126:305-309.